Celularity Inc. (CELU)
2.42
-0.02 (-0.82%)
At close: Jan 28, 2025, 1:58 PM
undefined% (undefined)
| Bid | 2.41 |
| Market Cap | 54.41M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -100.39 |
| PE Ratio (ttm) | -0.02 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | 2.51 |
| Volume | 21,322 |
| Avg. Volume (20D) | 1,187,332 |
| Open | 2.54 |
| Previous Close | 2.44 |
| Day's Range | 2.42 - 2.59 |
| 52-Week Range | 1.30 - 7.97 |
| Beta | undefined |
About CELU
Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, a placental-derived CAR-T therapy, which is in Phase I clinical trial for the treatment of B-cell malignancies; CYNK-...
Industry Biotechnology
Sector Healthcare
IPO Date Aug 8, 2019
Employees 120
Stock Exchange NASDAQ
Ticker Symbol CELU
Website https://www.celularity.com
2 months ago
+12.6%
Celularity shares are trading higher. The Nasdaq L...
Unlock content with
Pro Subscription
2 months ago
+113.1%
Celularity shares are trading higher after the company announced it raised its FY24 sales guidance from $50-$60M to $54-$60M.
